cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from Emory University, Medical Department in breast cancer provides new insights
December 18th, 2007
"Lipoxygenases (LOX) and cyclooxygenases (COX) are key mediators of arachidonic acid metabolism. Recently, studies have reported that human breast carcinomas aberrantly express LOX and cyclooxygenase-2 (COX-2), and that decreased levels of 15-lipoxygenase (15-LOX) and raised levels of COX-2 and 12-LOX have prognostic value in patients with breast cancer. 15-LOX was significanth, reduced with increasing stage, and in patients who developed metastatic disease, local recurrence,. patients developed local and/or died. With high COX-2. recurrence. died from breast cancer and had reduced disease-free and disease-related overall survival in estrogen receptor (ER)-negative but not ER-positive...
Source: cancer weekly (2007-12-18)
|
